Table 5.

Engraftment outcomes based on diagnosis. (A) All ASCTs during the study period. (B) ASCTs with cryopreserved PBSC products containing a cumulative TNC dose of > 1.63 × 10⁹/kg. (C) ASCTs with cryopreserved PBSC products containing a cumulative TNC dose of > 1.63 × 10⁹/kg with multi-day infusions

(A)
	Pre-policy change All infusions	Post-policy change All infusions	P-value
	Median days to neutrophil engraftment (n evaluable)
Multiple Myeloma	15 (117)	15 (223)	0.59
Non-Hodgkin’s Lymphoma/CLL	13 (118)	13 (173)	0.99
Other diagnosis	14 (60)	12 (100)	0.07
	Median days to platelet engraftment (n evaluable)
Multiple Myeloma	11 (106)	11 (199)	0.62
Non-Hodgkin’s Lymphoma/CLL	12 (111)	12 (158)	0.36
Other diagnosis	13 (56)	12 (97)	0.21

(B)
	Pre-policy change All infusions	Post-policy change All infusions	P-value
	Median days to neutrophil engraftment (n evaluable)
Multiple Myeloma	14 (19)	15 (44)	0.39
Non-Hodgkin’s Lymphoma/CLL	14 (43)	14 (60)	0.40
Other diagnosis	13 (14)	13 (17)	0.60
	Median days to platelet engraftment (n evaluable)
Multiple Myeloma	14 (17)	12.5 (40)	0.09
Non-Hodgkin’s Lymphoma/CLL	12 (41)	13 (54)	0.33
Other diagnosis	12.5 (12)	14 (15)	0.68

(C)
	Pre-policy cohort Number of Infusions			Post-policy cohort Number of Infusions
	1	2	>2	1	2	>2
	Median days to neutrophil engraftment (n evaluable)
Multiple Myeloma	14.5 (12)	14 (7)	--	16 (1)	15 (37)	15 (6)
Non-Hodgkin’s Lymphoma/CLL	14 (34)	14 (7)	14.5 (2)	16.5 (2)	14 (33)	14 (25)
Other diagnosis	14 (11)	11 (3)	--	10 (5)	12.5 (6)	16.5 (6)
	Median days to platelet engraftment (n evaluable)
Multiple Myeloma	15 (12)	12 (5)	--	20 (1)	12 (34)	15 (5)
Non-Hodgkin’s Lymphoma/CLL	12 (34)	14.5 (6)	12 (1)	11.5 (2)	12 (31)	13 (21)
Other diagnosis	12.5 (10)	16.5 (2)	--	12 (5)	21 (5)	14 (5)